Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls

Bun Hee Lee, Yong Ku Kim

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Nitric oxide (NO) is believed to have a role in the pathophysiology of schizophrenia. We examined plasma levels of NO metabolites in patients with schizophrenia and normal controls. We also determined the impact of 6-week risperidone treatment on circulating NO metabolites in patients with schizophrenia. Method: Plasma NO metabolite (NOx) levels were measured in 55 schizophrenia patients before and after 6-week treatment with risperidone and in 55 normal controls. Severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS) for schizophrenia. NOx levels were estimated by the Griess method. Results: Pre-treatment plasma NOx levels in schizophrenia patients (8.97 ± 6.74 μmol/L) were lower than those of normal controls (14.51 ± 6.30 μmol/L) (p < 0.01). Schizophrenia patients had lower post-treatment NOx levels (10.99 ± 8.31 μmol/L) than those of normal controls (p < 0.01). There was marginal significant change between plasma NOx levels before and after 6-week treatment (p = 0.056). Moreover, in 37 treatment responders (≥ 30% improvement in PANSS score), post-treatment plasma NOx significantly increased in comparison to pre-treatment NOx (p = 0.028). Conclusions: Plasma levels of NOx in patients with schizophrenia were significantly lower than normal controls both before and after the treatment. Our findings suggest that the improvement of psychiatric symptoms can lead to partially normalize a deficiency of NO after treatment in schizophrenia patients. Our findings support the hypothesis that the NO system is dampened in schizophrenia.

Original languageEnglish
Pages (from-to)36-43
Number of pages8
JournalSchizophrenia Research
Volume104
Issue number1-3
DOIs
Publication statusPublished - 2008 Sep 1

Fingerprint

Antipsychotic Agents
Schizophrenia
Nitric Oxide
Therapeutics
Risperidone
Psychiatry

Keywords

  • Nitric oxide
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. / Lee, Bun Hee; Kim, Yong Ku.

In: Schizophrenia Research, Vol. 104, No. 1-3, 01.09.2008, p. 36-43.

Research output: Contribution to journalArticle

@article{4aaa3204648e4486bb230c1702072741,
title = "Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls",
abstract = "Background: Nitric oxide (NO) is believed to have a role in the pathophysiology of schizophrenia. We examined plasma levels of NO metabolites in patients with schizophrenia and normal controls. We also determined the impact of 6-week risperidone treatment on circulating NO metabolites in patients with schizophrenia. Method: Plasma NO metabolite (NOx) levels were measured in 55 schizophrenia patients before and after 6-week treatment with risperidone and in 55 normal controls. Severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS) for schizophrenia. NOx levels were estimated by the Griess method. Results: Pre-treatment plasma NOx levels in schizophrenia patients (8.97 ± 6.74 μmol/L) were lower than those of normal controls (14.51 ± 6.30 μmol/L) (p < 0.01). Schizophrenia patients had lower post-treatment NOx levels (10.99 ± 8.31 μmol/L) than those of normal controls (p < 0.01). There was marginal significant change between plasma NOx levels before and after 6-week treatment (p = 0.056). Moreover, in 37 treatment responders (≥ 30{\%} improvement in PANSS score), post-treatment plasma NOx significantly increased in comparison to pre-treatment NOx (p = 0.028). Conclusions: Plasma levels of NOx in patients with schizophrenia were significantly lower than normal controls both before and after the treatment. Our findings suggest that the improvement of psychiatric symptoms can lead to partially normalize a deficiency of NO after treatment in schizophrenia patients. Our findings support the hypothesis that the NO system is dampened in schizophrenia.",
keywords = "Nitric oxide, Risperidone, Schizophrenia",
author = "Lee, {Bun Hee} and Kim, {Yong Ku}",
year = "2008",
month = "9",
day = "1",
doi = "10.1016/j.schres.2008.06.005",
language = "English",
volume = "104",
pages = "36--43",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls

AU - Lee, Bun Hee

AU - Kim, Yong Ku

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Background: Nitric oxide (NO) is believed to have a role in the pathophysiology of schizophrenia. We examined plasma levels of NO metabolites in patients with schizophrenia and normal controls. We also determined the impact of 6-week risperidone treatment on circulating NO metabolites in patients with schizophrenia. Method: Plasma NO metabolite (NOx) levels were measured in 55 schizophrenia patients before and after 6-week treatment with risperidone and in 55 normal controls. Severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS) for schizophrenia. NOx levels were estimated by the Griess method. Results: Pre-treatment plasma NOx levels in schizophrenia patients (8.97 ± 6.74 μmol/L) were lower than those of normal controls (14.51 ± 6.30 μmol/L) (p < 0.01). Schizophrenia patients had lower post-treatment NOx levels (10.99 ± 8.31 μmol/L) than those of normal controls (p < 0.01). There was marginal significant change between plasma NOx levels before and after 6-week treatment (p = 0.056). Moreover, in 37 treatment responders (≥ 30% improvement in PANSS score), post-treatment plasma NOx significantly increased in comparison to pre-treatment NOx (p = 0.028). Conclusions: Plasma levels of NOx in patients with schizophrenia were significantly lower than normal controls both before and after the treatment. Our findings suggest that the improvement of psychiatric symptoms can lead to partially normalize a deficiency of NO after treatment in schizophrenia patients. Our findings support the hypothesis that the NO system is dampened in schizophrenia.

AB - Background: Nitric oxide (NO) is believed to have a role in the pathophysiology of schizophrenia. We examined plasma levels of NO metabolites in patients with schizophrenia and normal controls. We also determined the impact of 6-week risperidone treatment on circulating NO metabolites in patients with schizophrenia. Method: Plasma NO metabolite (NOx) levels were measured in 55 schizophrenia patients before and after 6-week treatment with risperidone and in 55 normal controls. Severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS) for schizophrenia. NOx levels were estimated by the Griess method. Results: Pre-treatment plasma NOx levels in schizophrenia patients (8.97 ± 6.74 μmol/L) were lower than those of normal controls (14.51 ± 6.30 μmol/L) (p < 0.01). Schizophrenia patients had lower post-treatment NOx levels (10.99 ± 8.31 μmol/L) than those of normal controls (p < 0.01). There was marginal significant change between plasma NOx levels before and after 6-week treatment (p = 0.056). Moreover, in 37 treatment responders (≥ 30% improvement in PANSS score), post-treatment plasma NOx significantly increased in comparison to pre-treatment NOx (p = 0.028). Conclusions: Plasma levels of NOx in patients with schizophrenia were significantly lower than normal controls both before and after the treatment. Our findings suggest that the improvement of psychiatric symptoms can lead to partially normalize a deficiency of NO after treatment in schizophrenia patients. Our findings support the hypothesis that the NO system is dampened in schizophrenia.

KW - Nitric oxide

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=50549088246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549088246&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2008.06.005

DO - 10.1016/j.schres.2008.06.005

M3 - Article

VL - 104

SP - 36

EP - 43

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -